welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy
source: Neuromuscular Disorders
year: 2016
authors: Cuixia Tian, Brenda L. Wong, Lindsey Hornung, Jane C. Khoury, Lauren Miller, Jean Bange, Irina Rybalsky, Meilan M. Rutter
summary/abstract:Osteoporosis is a major problem in boys with Duchenne Muscular Dystrophy (DMD), attributable to muscle weakness and glucocorticoid therapy. Consensus regarding bone health assessment and management is lacking. Lumbar spine areal bone mineral density (defined as bone mass per area of bone) by dual-energy X-ray absorptiometry (DXA) is frequently the primary measure used, but has limitations for boys with DMD.
We retrospectively studied 292 ambulant glucocorticoid-treated boys with DMD categorized by functional mobility score, FMS 1, 2 or 3. We assessed DXA whole body and lumbar spine areal bone mineral density and content Z-scores adjusted for age and height, lateral distal femur areal bone mineral density Z-scores, frequency of fractures, and osteoporosis by International Society for Clinical Densitometry 2013 criteria. Whole body and femoral DXA indices decreased, while spine fractures increased, with declining motor function. Lumbar spine areal bone mineral density Z-scores appeared to improve with declining motor function. Bone mineral content Z-scores were consistently lower than corresponding bone mineral density Z-scores.
Our findings highlight the complexity of assessing bone health in boys with DMD. Bone health indices worsened with declining motor function in ambulant boys, but interpretation was affected by measure and skeletal site examined. Whole body bone mineral content may be a valuable measure in boys with DMD. Lumbar spine areal bone mineral density Z-score as an isolated measure could be misleading. Comprehensive management of osteoporosis in boys with DMD should include vertebral fracture assessment.
organization: Cincinnati Children's Hospital Medical Center, USA; University of Cincinnati College of Medicine, USA; University of Connecticut, USADOI: 10.1016/j.nmd.2016.08.011
read more
rareRelated
-
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients...PTC Therapeutics, Inc. today announced t...
-
Intermittent PTH Treatment Improves Bone and Muscle in Glucocorticoid Treated Mdx Mice: A Model of Duchenne Muscular...Duchenne Muscular Dystrophy (DMD) is a p...
-
CoQ10 and Prednisone in Non-Ambulatory DMDThis study will help determine if CoQ10 ...
-
Emflaza Supply Not Affected by COVID-19 Pandemic, PTC Therapeutics SaysThe supply of Emflaza (deflazacort), a t...
-
The evaluation of bone age in patients with Duchenne muscular dystrophy on long-term glucocorticoid treatmentLong-term treatment with glucocorticoids...
-
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenn...Background:Corticosteroid treatment is c...
-
Recovering From a Broken Leg – Getting Back On Your FeetJennifer Wallace-Valdes, PT explains wha...